Literature DB >> 3091279

Male fertility regulation: recent advances.

G M Waites.   

Abstract

Acceptable antifertility drugs for men are proving difficult to produce. Such drugs must aim to achieve complete azoospermia over a long period. This requirement may be relaxed only if it can be shown that the residual sperm produced by men whose spermatogenesis has been suppressed by antifertility drugs to oligospermia are incapable of fertilizing ova. Hormonal methods involving suppression of the secretion of gonadotrophin hormones by the pituitary gland invariably require androgen supplementation, and the use of steroids either alone or in combination requires careful monitoring for their side-effects. A chemical (non-hormonal) approach involving the incapacitation of sperm in the epididymis has been shown to be feasible in animal studies using alpha-chlorohydrin and 6-chloro-6-deoxy sugars, although such compounds cannot be developed for human use because of their toxicity. Immunological approaches have the inherent problem of delivery of the antibody to the target. While the search for new and safer chemical and hormonal approaches goes on, the recent evidence that vasectomy offers a safe surgical option leaves responsible men with some choice to add to the condom.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091279      PMCID: PMC2490936     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  9 in total

Review 1.  Inhibin: from concept to reality.

Authors:  P Franchimont; J Verstraelen-Proyard; M T Hazee-Hagelstein; C Renard; A Demoulin; J P Bourguignon; J Hustin
Journal:  Vitam Horm       Date:  1979       Impact factor: 3.421

2.  Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-beta.

Authors:  A J Mason; J S Hayflick; N Ling; F Esch; N Ueno; S Y Ying; R Guillemin; H Niall; P H Seeburg
Journal:  Nature       Date:  1985 Dec 19-1986 Jan 1       Impact factor: 49.962

Review 3.  Inhibin: 1985 update on action and purification.

Authors:  F H de Jong; D M Robertson
Journal:  Mol Cell Endocrinol       Date:  1985-09       Impact factor: 4.102

4.  Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception.

Authors:  D Delanoe; B Fougeyrollas; L Meyer; P Thonneau
Journal:  Lancet       Date:  1984-02-04       Impact factor: 79.321

Review 5.  Gossypol: a potential antifertility agent for males.

Authors:  S Z Qian; Z G Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  1984       Impact factor: 13.820

6.  Active immunization with follicle-stimulating hormone for fertility control: a 4 1/2-year study in male rhesus monkeys.

Authors:  B R Srinath; E J Wickings; C Witting; E Nieschlag
Journal:  Fertil Steril       Date:  1983-07       Impact factor: 7.329

7.  Reversible inhibition of testicular function by a gonadotropin hormone-releasing hormone antagonist in monkeys (Macaca fascicularis).

Authors:  G F Weinbauer; F J Surmann; F B Akhtar; G V Shah; B H Vickery; E Nieschlag
Journal:  Fertil Steril       Date:  1984-12       Impact factor: 7.329

8.  Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion.

Authors:  T Schürmeyer; U A Knuth; C W Freischem; J Sandow; F B Akhtar; E Nieschlag
Journal:  J Clin Endocrinol Metab       Date:  1984-07       Impact factor: 5.958

9.  Vasectomy and health. Results from a large cohort study.

Authors:  F J Massey; G S Bernstein; W M O'Fallon; L M Schuman; A H Coulson; R Crozier; J S Mandel; R B Benjamin; H W Berendes; P C Chang
Journal:  JAMA       Date:  1984 Aug 24-31       Impact factor: 56.272

  9 in total
  1 in total

1.  The effect of vasectomy on the production of plasma luteinizing hormone and follicle stimulating hormone in man.

Authors:  K Glavind; N R Lauritsen; M Kløve-Mogensen; J Carl
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.